

FIG. 1




FIG. 2A

Anti-CD19 scFv	Linker	Anti-CD22 scFv	Flag	HIS
Anti-CD22 scFv	Linker	Anti-CD19 scFv	Flag	HIS

FIG. 2B

Leader	scFv1	Linker	scFv2	Hinge	TM	41BB	CD3z
--------	-------	--------	-------	-------	----	------	------

Leader	scFv1	Linker	scFv2	Hinge	TM	41BB	CD3z	T2A	EGFRt
--------	-------	--------	-------	-------	----	------	------	-----	-------





FIG. 3

FIG. 4A


EPC-001-19



Detected by Anti-EGFR AF647

FIG. 4B

EPC-001-19



Detected by Human CD22 AF647

FIG. 5A




FIG. 5B




FIG. 5C





FIG. 5D






FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7




FIG. 8




FIG. 9

Effector : Target
Ratio at 1:1
7-day assay




FIG. 10A




FIG. 10B

FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D





FIG. 11E






FIG. 12A

FIG. 12B

Group 2: EPC-001-23 (0.125e6) PBMC Ratio Day 19 Day33




FIG. 12C

Group 3: EPC-001-23 (0.25e6) PBMC Ratio Day 19 Day33




FIG. 12D




FIG. 12E




FIG. 13A





FIG. 13B






FIG. 14B

FIG. 14A

FIG. 15




FIG. 16B




FIG. 16A




FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 20C




FIG. 21A




FIG. 21B





FIG. 21C






FIG. 22A




FIG. 22B




FIG. 23A




FIG. 23B